The Union Budget 2026–27 has unveiled Biopharma SHAKTI, a national strategy aimed at positioning India as a global hub for biopharmaceutical manufacturing through strengthened healthcare innovation, research, and technology-led growth.
An acronym for Strategy for Healthcare Advancement through Knowledge, Technology and Innovation, Biopharma SHAKTI will be launched with a proposed outlay of ₹10,000 crore over the next five years, signalling the government’s push to scale India’s capabilities in advanced biologics and biosimilars.
Under the initiative, the government plans to build a robust ecosystem for the domestic production of biologics and biosimilars, reducing import dependence while boosting export competitiveness. A key pillar of the strategy includes the creation of a biopharma-focused academic and research network, with the establishment of three new National Institutes of Pharmaceutical Education and Research (NIPERs) and the upgradation of seven existing institutes.
The initiative will also strengthen India’s clinical research infrastructure through the creation of a network of over 1,000 accredited clinical trial sites, aimed at accelerating drug development and improving global trust in India-led clinical research.
Biopharma SHAKTI aligns with the government’s broader vision to enhance India’s healthcare innovation ecosystem, attract global investments, and reinforce the country’s position in the global pharmaceutical value chain.
